Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Comparison of Vortioxetine and Sertraline for Treatment of Major Depressive Disorder in Elderly Patients: A Double-Blind Randomized Trial Publisher Pubmed



Borhannejad F1 ; Shariati B2 ; Naderi S1 ; Shalbafan M2 ; Mortezaei A1 ; Sahebolzamani E1 ; Saeb A2 ; Hosein Mortazavi S1 ; Kamalzadeh L2 ; Aqamolaei A1 ; Ali Noorbala A3 ; Namazishabestari A4 ; Akhondzadeh S1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Mental Health Research Center, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Psychosomatic Research Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Geriatric, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Clinical Pharmacy and Therapeutics Published:2020


Abstract

What is known and objective: Major depressive disorder (MDD) is a complex disease and one of the leading contributors to disease burden throughout the world. In the current study, we explored the efficacy and tolerability of vortioxetine versus sertraline on symptoms of depression in elderly patients with MDD. Methods: Sixty patients diagnosed with MDD (based on DSM-5) and Hamilton Depression Rating Scale (HAM-D) score ≥ 19 were entered into a randomized double-blind study and were randomized to receive either vortioxetine (15 mg daily) or sertraline (75 mg daily) for six weeks. Patients were assessed using the HAM-D scale at baseline and weeks 3 and 6. Changes in HAM-D score, response rates, remission rate and time to response or remission were also compared between the two study groups. Results and Discussion: Fifty patients completed the trial after six weeks. General linear model repeated measures demonstrated no difference in trend of the two treatment groups (P =.897). There was no significantly different improvement in the HDRS scores from baseline to weeks 3 and 6, as well. Differences in response rate, remission rate, time to response and time to remission periods were not statistically significant. Finally, there was not any significantly difference between the two study groups in the frequency of adverse events. What is new and conclusion: This study showed no significant differences in the efficacy and safety of vortioxetine in comparison with sertraline in order for it to be used safely for treatment of major depressive disorder in elderly patients. © 2020 John Wiley & Sons Ltd
Related Docs
View other Related Docs
1. Vortioxetine As Adjunctive Therapy to Risperidone for Treatment of Patients With Chronic Schizophrenia: A Randomised, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Psychopharmacology (2020)
2. Efficacy and Safety of Tipepidine As Adjunctive Therapy in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Psychiatry and Clinical Neurosciences (2021)
3. Cinnamomum Tamala As an Adjuvant Therapy in the Treatment of Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial With Placebo Control, Advances in Integrative Medicine (2020)
4. Cilostazol As an Adjunctive Treatment in Major Depressive Disorder: A Pilot Randomized, Double-Blind, and Placebo-Controlled Clinical Trial, Psychopharmacology (2022)
5. 5-Hydroxytryptophan As Adjuvant Therapy in Treatment of Moderate to Severe Obsessive-Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, International Clinical Psychopharmacology (2020)
6. Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Journal of Clinical Pharmacy and Therapeutics (2017)
7. The Glutamatergic System in Depression: A Review of the Clinical Evidence of Medications and Supplements Affecting Through It, Journal of Iranian Medical Council (2024)
8. L-Carnosine Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Affective Disorders (2020)
Experts (# of related papers)
View all Related Experts
Shahin Akhondzadeh Basti (22)
Nazila Shahmansouri (4)
Other Related Docs
9. Pentoxifylline for Treatment of Major Depression After Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychosomatic Research (2021)
10. Sulforaphane As an Adjunctive Treatment for Irritability in Children With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Psychiatry and Clinical Neurosciences (2020)
11. Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial, International Journal of Neuropsychopharmacology (2020)
12. Efficacy and Safety of Pentoxifylline Combination Therapy in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, International Clinical Psychopharmacology (2021)
13. Celecoxib for the Treatment of Mild-To-Moderate Depression Due to Acute Brucellosis: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2015)
14. The Effects of Alcoholic Extract of Saffron (Crocus Satious L.) on Mild to Moderate Comorbid Depression-Anxiety, Sleep Quality, and Life Satisfaction in Type 2 Diabetes Mellitus: A Double-Blind, Randomized and Placebo-Controlled Clinical Trial, Complementary Therapies in Medicine (2018)
15. Does Oral Administration of Ketamine Accelerate Response to Treatment in Major Depressive Disorder? Results of a Double-Blind Controlled Trial, Journal of Affective Disorders (2018)
16. Efficacy of Gemfibrozil As an Adjunct to Sertraline in Major Depressive Disorder, a Double-Blind, Randomized, and Placebo-Controlled Clinical Trial, Iranian Journal of Psychiatry (2021)
17. Pioglitazone Adjunctive Therapy for Depressive Episode of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Depression and Anxiety (2015)
18. Simvastatin As an Adjuvant Therapy to Fluoxetine in Patients With Moderate to Severe Major Depression: A Double-Blind Placebo-Controlled Trial, Journal of Psychopharmacology (2015)
19. Crocus Sativus L. Versus Methylphenidate in Treatment of Children With Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study, Journal of Child and Adolescent Psychopharmacology (2019)
20. Hab-O Shefa, a Persian Medicine Compound for Maintenance Treatment of Opioid Dependence: Randomized Placebo-Controlled Clinical Trial, Journal of Alternative and Complementary Medicine (2020)
21. Simvastatin Versus Atorvastatin for Improving Mild to Moderate Depression in Post-Coronary Artery Bypass Graft Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Affective Disorders (2015)
22. Celecoxib Adjunctive Therapy for Acute Bipolar Mania: A Randomized, Double-Blind, Placebo-Controlled Trial, Bipolar Disorders (2015)
23. Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Psychiatry and Clinical Neurosciences (2021)